Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | ryanodine receptor related | 0.0316 | 0.5799 | 0.7496 |
Loa Loa (eye worm) | thioredoxin reductase | 0.0108 | 0.0561 | 0.1003 |
Schistosoma mansoni | inositol 145-trisphosphate receptor | 0.0257 | 0.4319 | 0.5582 |
Loa Loa (eye worm) | glutathione reductase | 0.0108 | 0.0561 | 0.1003 |
Plasmodium vivax | glutathione reductase, putative | 0.0108 | 0.0561 | 0.5 |
Toxoplasma gondii | thioredoxin reductase | 0.0108 | 0.0561 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0226 | 0.3536 | 0.6324 |
Plasmodium falciparum | thioredoxin reductase | 0.0108 | 0.0561 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0308 | 0.5592 | 1 |
Brugia malayi | Ryanodine Receptor TM 4-6 family protein | 0.0316 | 0.5799 | 0.555 |
Loa Loa (eye worm) | hypothetical protein | 0.0302 | 0.5445 | 0.9738 |
Echinococcus multilocularis | ryanodine receptor 44f | 0.0175 | 0.2263 | 0.5722 |
Trypanosoma brucei | inositol 1,4,5-trisphosphate receptor | 0.0266 | 0.4555 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0181 | 0.241 | 1 |
Echinococcus multilocularis | ryanodine receptor 44f | 0.0226 | 0.3536 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0257 | 0.4319 | 0.7724 |
Mycobacterium tuberculosis | NADPH-dependent mycothiol reductase Mtr | 0.0108 | 0.0561 | 0.5 |
Echinococcus granulosus | ryanodine receptor 44f | 0.0175 | 0.2263 | 0.5722 |
Schistosoma mansoni | inositol 145-trisphosphate receptor | 0.0393 | 0.7737 | 1 |
Plasmodium falciparum | glutathione reductase | 0.0108 | 0.0561 | 0.5 |
Plasmodium vivax | thioredoxin reductase, putative | 0.0108 | 0.0561 | 0.5 |
Echinococcus granulosus | ryanodine receptor 44f | 0.0226 | 0.3536 | 1 |
Trypanosoma cruzi | inositol 1,4,5-trisphosphate receptor, putative | 0.0266 | 0.4555 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.